IMC-18F1

BIOLOGICAL2 trials

Sponsors

Eli Lilly and Company

Conditions

Advanced Solid TumorsBreast Cancer

Phase 1

Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy

CompletedNCT00782002

Eli Lilly and CompanyAdvanced Solid Tumors

Start: 2006-07-31End: 2009-11-30Updated: 2010-09-30

Phase 2

Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

CompletedNCT01234402

Eli Lilly and CompanyBreast Cancer

Start: 2011-03-31End: 2017-07-31Updated: 2019-08-14